Targeting dendritic cells with biomaterials: developing the next generation of vaccines

Trends in Immunology

Volumn 27, Issue 12, 2006, Pages 573-579

  Reddy, Sai T ^a   Swartz, Melody A ^a   Hubbell, Jeffrey A ^a  

^a EPFL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM HYDROXIDE; ALUMINUM PHOSPHATE; BIOMATERIAL; DRUG VEHICLE; GAMMA INTERFERON; GLYCOPROTEIN P 15095; LIPOPOLYSACCHARIDE; LIPOSOME; MACROGOL; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINYLALANYL DIPALMITOYLPHOSPHATIDYLETHANOLAMINE; PHOSPHORYL LIPID A; POLY(ORTHO ESTER); POLYANHYDRIDE; POLYCARBONATE; POLYGLYCOLIC ACID; POLYLACTIC ACID; POLYMER; QS 21; SAPONIN;

ANTIBODY PRODUCTION; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; AUTOIMMUNE DISEASE; BIOENGINEERING; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL MATURATION; CELL MIGRATION; CELLULAR IMMUNITY; CLINICAL TRIAL; DENDRITIC CELL; DRUG DEGRADATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; ENDOCYTOSIS; HUMAN; HYDROPHILICITY; HYDROPHOBICITY; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; IMMUNOSTIMULATION; IMMUNOTHERAPY; INFLAMMATION; INNATE IMMUNITY; LANGERHANS CELL; LYMPH NODE; NANOPARTICLE; NONHUMAN; ORGAN TRANSPLANTATION; PHAGOCYTE; PHAGOCYTOSIS; REVIEW; SHOCK; T LYMPHOCYTE ACTIVATION; TARGET CELL; TUMOR IMMUNITY; VACCINE PRODUCTION;

ADJUVANTS, PHARMACEUTIC; ANIMALS; ANTIGENS; BIOCOMPATIBLE MATERIALS; DENDRITIC CELLS; DRUG DESIGN; HUMANS; LIPOSOMES; LYMPH NODES; MODELS, IMMUNOLOGICAL; NANOPARTICLES; POLYMERS; VACCINES; VEHICLES;

EID: 33750728433     PISSN: 14714906     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.it.2006.10.005     Document Type: Review

References (80)

1. Banchereau J., and Palucka A.K. Dendritic cells as therapeutic vaccines against cancer. Nat. Rev. Immunol. 5 (2005) 296-306
2. Nestle F.O., et al. Dendritic cells: on the move from bench to bedside. Nat. Med. 7 (2001) 761-765
3. Banchereau J., and Steinman R.M. Dendritic cells and the control of immunity. Nature 392 (1998) 245-252
4. O'Hagan D.T., and Valiante N.M. Recent advances in the discovery and delivery of vaccine adjuvants. Nat. Rev. Drug Discov. 2 (2003) 727-735
5. Gatza E., and Okada C.Y. Tumor cell lysate-pulsed dendritic cells are more effective than TCR Id protein vaccines for active immunotherapy of T cell lymphoma. J. Immunol. 169 (2002) 5227-5235
6. Timmerman J.M., et al. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood 99 (2002) 1517-1526
7. Wang R.F., and Wang H.Y. Enhancement of antitumor immunity by prolonging antigen presentation on dendritic cells. Nat. Biotechnol. 20 (2002) 149-154
8. Mahnke K., et al. Targeting of antigens to activated dendritic cells in vivo cures metastatic melanoma in mice. Cancer Res. 65 (2005) 7007-7012
9. Hauser H., et al. Secretory heat-shock protein as a dendritic cell-targeting molecule: a new strategy to enhance the potency of genetic vaccines. Gene Ther. 11 (2004) 924-932
10. Davis N.L., et al. Alphavirus replicon particles as candidate HIV vaccines. IUBMB Life 53 (2002) 209-211
11. Bonifaz L.C., et al. In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination. J. Exp. Med. 199 (2004) 815-824
12. Peppas N.A., and Langer R. New challenges in biomaterials. Science 263 (1994) 1715-1720
13. Lutolf M.P., and Hubbell J.A. Synthetic biomaterials as instructive extracellular microenvironments for morphogenesis in tissue engineering. Nat. Biotechnol. 23 (2005) 47-55
14. Napoli A., et al. Oxidation-responsive polymeric vesicles. Nat. Mater. 3 (2004) 183-189
15. Discher D.E., and Eisenberg A. Polymer vesicles. Science 297 (2002) 967-973
16. Tang L., et al. Molecular determinants of acute inflammatory responses to biomaterials. J. Clin. Invest. 97 (1996) 1329-1334
17. Tang L., and Eaton J.W. Inflammatory responses to biomaterials. Am. J. Clin. Pathol. 103 (1995) 466-471
18. Hu W.J., et al. Molecular basis of biomaterial-mediated foreign body reactions. Blood 98 (2001) 1231-1238
19. Preis I., and Langer R.S. A single-step immunization by sustained antigen release. J. Immunol. Methods 28 (1979) 193-197
20. Langer R., and Folkman J. Polymers for the sustained release of proteins and other macromolecules. Nature 263 (1976) 797-800
21. Lanzavecchia A. Mechanisms of antigen uptake for presentation. Curr. Opin. Immunol. 8 (1996) 348-354
22. DL-lactide-co-glycolide) microspheres for the delivery of DNA to human-derived macrophages and dendritic cells. J. Control. Release 76 (2001) 149-168
23. Elamanchili P., et al. Characterization of poly(D,L-lactic-co-glycolic acid) based nanoparticulate system for enhanced delivery of antigens to dendritic cells. Vaccine 22 (2004) 2406-2412
24. Copland M.J., et al. Liposomal delivery of antigen to human dendritic cells. Vaccine 21 (2003) 883-890
25. Rock K.L., and Shen L. Cross-presentation: underlying mechanisms and role in immune surveillance. Immunol. Rev. 207 (2005) 166-183
26. Norbury C.C., et al. Class I MHC presentation of exogenous soluble antigen via macropinocytosis in bone marrow macrophages. Immunity 3 (1995) 783-791
27. Kovacsovics-Bankowski M., and Rock K.L. A phagosome-to-cytosol pathway for exogenous antigens presented on MHC class I molecules. Science 267 (1995) 243-246
28. Rock K.L., et al. Presentation of exogenous antigen with class I major histocompatibility complex molecules. Science 249 (1990) 918-921
29. Sallusto F., et al. Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products. J. Exp. Med. 182 (1995) 389-400
30. Lutsiak M.E., et al. Analysis of poly(D,L-lactic-co-glycolic acid) nanosphere uptake by human dendritic cells and macrophages in vitro. Pharm. Res. 19 (2002) 1480-1487
31. Thiele L., et al. Phagocytosis and phagosomal fate of surface-modified microparticles in dendritic cells and macrophages. Pharm. Res. 20 (2003) 221-228
32. Wang D., et al. Encapsulation of plasmid DNA in biodegradable poly(D, L-lactic-co-glycolic acid) microspheres as a novel approach for immunogene delivery. J. Control. Release 57 (1999) 9-18
33. Newman K.D., et al. Ovalbumin peptide encapsulated in poly(D,L lactic-co-glycolic acid) microspheres is capable of inducing a T helper type 1 immune response. J. Control. Release 54 (1998) 49-59
34. Newman K.D., et al. Uptake of poly(D,L-lactic-co-glycolic acid) microspheres by antigen-presenting cells in vivo. J. Biomed. Mater. Res. 60 (2002) 480-486
35. Pai Kasturi S., et al. Prophylactic anti-tumor effects in a B cell lymphoma model with DNA vaccines delivered on polyethylenimine (PEI) functionalized PLGA microparticles. J. Control. Release 113 (2006) 261-270
36. Singh M., et al. Cationic microparticles: a potent delivery system for DNA vaccines. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 811-816
37. McKeever U., et al. Protective immune responses elicited in mice by immunization with formulations of poly(lactide-co-glycolide) microparticles. Vaccine 20 (2002) 1524-1531
38. Jiang W., et al. Biodegradable poly(lactic-co-glycolic acid) microparticles for injectable delivery of vaccine antigens. Adv. Drug Deliv. Rev. 57 (2005) 391-410
39. Denis-Mize K.S., et al. Plasmid DNA adsorbed onto cationic microparticles mediates target gene expression and antigen presentation by dendritic cells. Gene Ther. 7 (2000) 2105-2112
40. Bennewitz N.L., and Babensee J.E. The effect of the physical form of poly(lactic-co-glycolic acid) carriers on the humoral immune response to co-delivered antigen. Biomaterials 26 (2005) 2991-2999
41. Avrameas A., et al. Expression of a mannose/fucose membrane lectin on human dendritic cells. Eur. J. Immunol. 26 (1996) 394-400
42. Murthy N., et al. Bioinspired pH-responsive polymers for the intracellular delivery of biomolecular drugs. Bioconjug. Chem. 14 (2003) 412-419
43. Wang C., et al. Molecularly engineered poly(ortho ester) microspheres for enhanced delivery of DNA vaccines. Nat. Mater. 3 (2004) 190-196
44. Kwon Y.J., et al. In vivo targeting of dendritic cells for activation of cellular immunity using vaccine carriers based on pH-responsive microparticles. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 18264-18268
45. Singh M., and O'Hagan D. Advances in vaccine adjuvants. Nat. Biotechnol. 17 (1999) 1075-1081
46. Gupta R.K., and Siber G.R. Adjuvants for human vaccines - current status, problems and future prospects. Vaccine 13 (1995) 1263-1276
47. Gupta R.K. Aluminum compounds as vaccine adjuvants. Adv. Drug Deliv. Rev. 32 (1998) 155-172
48. Persing D.H., et al. Taking toll: lipid A mimetics as adjuvants and immunomodulators. Trends Microbiol. 10 (2002) S32-S37
49. Hunter R.L. Overview of vaccine adjuvants: present and future. Vaccine 20 (2002) S7-S12
50. Todd C.W., et al. Development of adjuvant-active nonionic block copolymers. Adv. Drug Deliv. Rev. 32 (1998) 199-223
51. Little S.R., et al. Poly-β amino ester-containing microparticles enhance the activity of nonviral genetic vaccines. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 9534-9539
52. Yoshida M., and Babensee J.E. Poly(lactic-co-glycolic acid) enhances maturation of human monocyte-derived dendritic cells. J. Biomed. Mater. Res. A 71 (2004) 45-54
53. Matsumoto M., et al. Establishment of a monoclonal antibody against human Toll-like receptor 3 that blocks double-stranded RNA-mediated signaling. Biochem. Biophys. Res. Commun. 293 (2002) 1364-1369
54. Heil F., et al. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science 303 (2004) 1526-1529
55. Barrick J.E., and Roberts R.W. Sequence analysis of an artificial family of RNA-binding peptides. Protein Sci. 11 (2002) 2688-2696
56. Wright J.R. Immunoregulatory functions of surfactant proteins. Nat. Rev. Immunol. 5 (2005) 58-68
57. Seong S.Y., and Matzinger P. Hydrophobicity: an ancient damage-associated molecular pattern that initiates innate immune responses. Nat. Rev. Immunol. 4 (2004) 469-478
58. Hunter R., et al. The adjuvant activity of nonionic block polymer surfactants. I. The role of hydrophile-lipophile balance. J. Immunol. 127 (1981) 1244-1250
59. van Broekhoven C.L., et al. Targeting dendritic cells with antigen-containing liposomes: a highly effective procedure for induction of antitumor immunity and for tumor immunotherapy. Cancer Res. 64 (2004) 4357-4365
60. Roth A., et al. Synthesis of thiol-reactive lipopeptide adjuvants. Incorporation into liposomes and study of their mitogenic effect on mouse splenocytes. Bioconjug. Chem. 15 (2004) 541-553
61. Espuelas S., et al. Effect of synthetic lipopeptides formulated in liposomes on the maturation of human dendritic cells. Mol. Immunol. 42 (2005) 721-729
62. Roberts M.J., et al. Chemistry for peptide and protein PEGylation. Adv. Drug Deliv. Rev. 54 (2002) 459-476
63. Lee H., and Park T.G. Preparation and characterization of mono-PEGylated epidermal growth factor: evaluation of in vitro biologic activity. Pharm. Res. 19 (2002) 845-851
64. Lee H., et al. N-terminal site-specific mono-PEGylation of epidermal growth factor. Pharm. Res. 20 (2003) 818-825
65. Randolph G.J., et al. Dendritic-cell trafficking to lymph nodes through lymphatic vessels. Nature Rev. Immunol. 5 (2005) 617-628
66. Pack D.W. Timing is everything. Nat. Mater. 3 (2004) 133-134
67. + T cell tolerance. Immunity 18 (2003) 713-720
68. Wilson N.S., and Villadangos J.A. Lymphoid organ dendritic cells: beyond the Langerhans cells paradigm. Immunol. Cell Biol. 82 (2004) 91-98
69. Wilson N.S., et al. Dendritic cells constitutively present self antigens in their immature state in vivo and regulate antigen presentation by controlling the rates of MHC class II synthesis and endocytosis. Blood 103 (2004) 2187-2195
70. Wilson N.S., et al. Most lymphoid organ dendritic cell types are phenotypically and functionally immature. Blood 102 (2003) 2187-2194
71. Sixt M., et al. The conduit system transports soluble antigens from the afferent lymph to resident dendritic cells in the T cell area of the lymph node. Immunity 22 (2005) 19-29
72. Villadangos J.A., et al. Control of MHC class II antigen presentation in dendritic cells: a balance between creative and destructive forces. Immunol. Rev. 207 (2005) 191-205
73. Heath W.R., et al. Cross-presentation, dendritic cell subsets, and the generation of immunity to cellular antigens. Immunol. Rev. 199 (2004) 9-26
74. Swartz M.A. The physiology of the lymphatic system. Adv. Drug Deliv. Rev. 50 (2001) 3-20
75. Reddy S.T., et al. A sensitive in vivo model for quantifying interstitial convective transport of injected macromolecules and nanoparticles. J. Appl. Physiol. 101 (2006) 1162-1169
76. Oussoren C., and Storm G. Liposomes to target the lymphatics by subcutaneous administration. Adv. Drug Deliv. Rev. 50 (2001) 143-156
77. Nishioka Y., and Yoshino H. Lymphatic targeting with nanoparticulate system. Adv. Drug Deliv. Rev. 47 (2001) 55-64
78. Oussoren C., et al. Lymphatic uptake and biodistribution of liposomes after subcutaneous injection. 2. Influence of liposomal size, lipid composition and lipid dose. Biochim. Biophys. Acta Biomembranes 1328 (1997) 261-272
79. Rehor A., et al. Oxidation-sensitive polymeric nanoparticles. Langmuir 21 (2005) 411-417
80. Reddy S.T., et al. In vivo targeting of dendritic cells in lymph nodes with poly(propylene sulfide) nanoparticles. J. Control. Release 112 (2006) 26-34